Laurus Labs Ltd management interview: Laurus Labs Q2: Revenue Jumps 33%, EBITDA Soars 86% – Can Growth Sustain? | Business News | ET Now
ET Now, 2026-10-30. Video: https://www.youtube.com/watch?v=Y-EPbOB_jKA
- Growth outlook: Record-quarter revenue rose 33% and EBITDA 86%, driven significantly by CDMO, alongside growth in oncology APIs and continued leadership in antiretrovirals. Management expects gross and EBITDA margins in the second half to remain similar to Q1 and Q2.
- Margin guidance: Gross margins were 63% in Q1 and Q2 and are expected to remain well above 60%; EBITDA margins have exceeded 30%. Management expects revenue growth and operating leverage to support EBITDA margins as R&D spending declines as a percentage of revenue.
- CDMO mix: CDMO already contributes a little above 40% of the business, and management expects it to contribute well above 50% by FY '30.
- Peptide expansion: The Vizag peptide facility is undergoing validations, with revenues expected in the next 18, 24 months. Laurus is also building a very large-scale second peptide plant.
- Acquisitions and Bio: Investments in a Hyderabad peptide-resin company and a Canada-based oligonucleotide R&D company strengthen Laurus’ capabilities; meaningful revenues may take 2 to 3 years. Bio revenue declined 38% due to campaign phasing, which management called transient, saying it remains confident in the segment and expects growth after a couple of more quarters.